Alpha 1-antitrypsin in Patients with Hepatocellular Carcinoma and Chronic Active Hepatitis
Overview
Affiliations
Forty-seven Italian patients suffering from hepatocellular carcinoma (HCC) and 58 patients with chronic active hepatitis (CAH) were screened for alpha 1-antitrypsin (alpha 1 AT) levels and types and compared with a previously screened healthy Italian population. Serum alpha 1 AT concentrations were significantly raised among the HCC patients compared to the controls, whereas the CAH group showed no differences. The incidence of non-M phenotypes (MS, MZ and S) is significantly higher in patients with HCC than in the CAH group and the controls. The mean age of HCC patients with a non-M phenotype is significantly lower than the mean age of HCC patients with an M phenotype.
Orphan drug development in alpha-1 antitypsin deficiency.
Trudzinski F, Presotto M, Buck E, Herth F, Ries M Sci Rep. 2022; 12(1):15497.
PMID: 36109566 PMC: 9477815. DOI: 10.1038/s41598-022-19707-2.
Megger D, Bracht T, Kohl M, Ahrens M, Naboulsi W, Weber F Mol Cell Proteomics. 2013; 12(7):2006-20.
PMID: 23462207 PMC: 3708182. DOI: 10.1074/mcp.M113.028027.
PI (alpha 1-Antitrypsin) subtypes: frequency of PI*M4 in several populations.
Klasen E, Bos A, Simmelink H Hum Genet. 1982; 62(2):139-41.
PMID: 6984414 DOI: 10.1007/BF00282302.
An association between alpha 1-antitrypsin phenotype and chronic liver disease.
Kishimoto Y, Yamada S, Hirayama C Hum Genet. 1990; 84(2):132-6.
PMID: 2153626 DOI: 10.1007/BF00208927.